BSD Medical has reported continued sales momentum by Terumo on the distribution of the MicroThermX Microwave Ablation system. BSD’s exclusive agreement with Terumo covers distribution of the MicroThermX in more than 100 countries, including Europe, Western Asia and Africa.
Cordis has announced receiving the CE mark for its Renlane renal denervation system for the treatment of patients with resistant hypertension and has completed the first successful cases in Europe.
Cordis Corporation announced that it has entered into an agreement with TriReme Medical that grants the company exclusive distribution rights for the Chocolate percutaneous transluminal angioplasty (PTA) balloon catheter.
Endologix has announced the Journal of Vascular Surgery s (JVS) e-publication of the data from the first prospective, multicentre, randomised clinical trial of a totally percutaneous approach (PEVAR) to endovascular abdominal aortic aneurysm repair (EVAR).
Results from the RELINE trial show that the Viabahn covered stent (Gore) conferred significantly better protection against target lesion revascularisation and had a significantly higher primary patency than percutaneous transluminal angioplasty.
The outcomes from our study on the efficacy and safety of percutaneous cryoablation, published recently in CardioVascular and Interventional Radiology, are the result of the most rigorous investigation on the subject to-date. These exceptional numbers (97%, five-year oncologic efficacy and 6% complication rate) however, are a double-edged sword. On one hand, they approach those of the gold standard, on the other, we must prove they are widely reproducible, writes Christos Georgiades
Deep vein thrombosis (DVT) often brings with it the risk of post-thrombotic syndrome (PTS), an under-recognized but serious complication that often causes long-term disability for patients. During March s DVT Awareness Month, the Society of Interventional Radiology wants to help patients and family members to better understand the long-term risks of DVT.
First Ten Patients Enrolled in U.S. Clinical Study that is Evaluating Treatment of Iliofemoral Venous Outflow Obstruction
A study that set out to assess the safety and efficacy of prostate artery embolization in small volume benign prostatic hyperplasia (<50cc) revealed that the procedure appears to offer positive clinical benefits for patients out to six months.
Men with benign prostatic hyperplasia can get relief from symptoms such as frequent night urination with prostatic artery embolization, suggests long-term research presented at the 26th annual International Symposium on Endovascular Therapy (ISET, 18–22 January, Miami, USA).
Following on from the news that Medtronic’s SYMPLICITY HTN-3 study failed to meets its primary efficacy endpoint, Covidien has announced it will exit its OneShot renal denervation programme. The company states that this "voluntary action" is primarily in response to a slower than expected development of the renal denervation market and that the decision resulted from Covidien’s regular review of strategic programmes and growth potential for various aspects of its product portfolio.
In the interventional world, technologies rapidly oscillate between being the high of the “next big thing” and then the low of being “killed off” with the publication of negative trials. Medtronic recently announced that its sham-controlled renal denervation study, SYMPLICITY HTN-3, failed to meet its primary efficacy. Now, Covidien has announced that it is "exiting" the OneShot Renal Denervation Program. Interventional News learns from leaders in the field that the watchword is: “wait for the publication”. “A critical analysis of the full dataset and study design are now imperative before the interventional community leaps to any conclusions about whether renal denervation works or not to control true resistant hypertension,” they say.
EKOS Corporation announced on 20 January 2014 the publication of the results of its ULTIMA (Ultrasound accelerated thrombolysis of pulmonary embolism) trial in Circulation. The announcement was made at the International Symposium on Endovascular Therapy (ISET) in Miami, USA.
Investigators from the MORE (Metastatic colorectal cancer liver metastases outcomes after radioembolization) study have released new findings at the American Society of Clinical Oncology’s 2014 Gastrointestinal Cancers Symposium confirming that standard laboratory tests are a valuable tool for predicting patient outcomes prior to Selective Internal Radiation Therapy (SIRT).
Cryoablation kills tumours and provides pain relief to patients whose cancer has spread to the bone and soft tissue, suggests research being presented at the 6th annual Symposium on Clinical Interventional Oncology (CIO), in collaboration with the International Symposium on Endovascular Therapy (ISET).
Cookies Sociales
Son esos botones que permiten compartir el contenido del sitio web en sus redes sociales (Facebook, Twitter y Linkedin, previo tu consentimiento y login) a través de sistemas totalmente gestionados por dichas redes sociales, así como los recursos (pej. videos) y material que se encuentra en nuestra web, y que de igual manera se presta y gestiona completamente por un tercero.
Si no acepta estas cookies, no podrá compartir nuestro contenido a través de los botones, y en su caso, no podrás visualizar el contenido de terceros que hayamos incrustado en el sitio.
No las utilizamos